A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia
Stopped early · Phase 1 · Has a placebo group
Conditions studied: Healthy Volunteers, Propionic Acidemia, Methylmalonic Acidemia, Organic Acidemia
In brief
The purpose of this study is to assess the safety, tolerability, PK and PD of BBP-671 in healthy volunteers and patients with Propionic Acidemia or Methylmalonic Acidemia.
Key facts
- Study ID
- NCT04836494
- Run by
- CoA Therapeutics, Inc., a BridgeBio company
- People needed
- 79
- Starts
- 2021-03-25
- Expected to finish
- 2023-11-20
- Last updated by the study team
- 2023-12-21
Who can join
Age: 15 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Community Health Clinic — Topeka, Indiana, United States
- UPMC Children's Hospital of Pittsburg — Pittsburgh, Pennsylvania, United States
- PPD Development, LP — Austin, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.